IP Library Granted Patent US 10,307,361
Granted Patent B2
US 10,307,361 · App. 15/820,093 · Granted Jun 4, 2019

Vesicles containing saccharide isomerate, hydrolyzed lupine protein, and intercorneocyte lipid mimetics as active ingredient, and composition for skin external application comprising the same

Inventors: Min-Hye Lee (Hwaseong-si, KR); Young-Chul Ko (Yongin-si, KR); Kang-Min Yoo (Ansan-si, KR); Seung-ki Hong (Daejeon, KR); Jin-Soo Lee (Seoul, KR)
Assignee: CMS LAB INC.
A61K8/645A61K8/14A61K8/345A61K8/361A61K8/553A61K8/60A61K8/63A61K8/68A61K8/73A61K8/9789A61Q19/00A61Q19/007A61K2800/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,307,361
App. No.
15/820,093
Granted
Jun 4, 2019
Kind
B2
Abstract

The present invention relates to a vesicle containing a saccharide isomerate, a hydrolyzed lupine protein, and an intercorneocyte lipid mimetics as an active ingredient, and a composition for skin external application including the vesicle, and more particularly, to a vesicle including: an aqueous phase part including a saccharide isomerate and a hydrolyzed lupine protein; and an oil phase part including an intercorneocyte lipid mimetics, lysolecithin, and glycerin. The vesicle includes the intercorneocyte lipid mimetics together with the saccharide isomerate and the hydrolyzed lupine protein as contents, so that the vesicle is excellent in a skin barrier recovery function and a skin moisturizing effect upon skin application. In addition, the vesicle is excellent in phase stability, so that the vesicle is suitable to be commercialized as various compositions for skin external application.

Claims (9)

1. A vesicle containing a saccharide isomerate, a hydrolyzed lupine protein, and an intercorneocyte lipid mimetics as an active ingredient, the vesicle comprising:

an oil phase part obtained by dispersing 10 wt % to 75 wt % of the intercorneocyte lipid mimetics and 1 wt % to 10 wt % of lysolecithin in 1 wt % to 20 wt % of glycerin; and

an aqueous phase part obtained by dissolving 0.01 wt % to 7 wt % of the saccharide isomerate and 0.01 wt % to 7 wt % of the hydrolyzed lupine protein in the balance of purified water,

wherein the intercorneocyte lipid mimetics includes 10 wt % to 70 wt % of an intercorneocyte lipid component, 0.1 wt % to 20 wt % of an amphoteric surfactant, 2 wt % to 20 wt % of saturated lecithin, 5 wt % to 20 wt % of glycerin, and the balance of purified water based on a total weight of the intercorneocyte lipid mimetics.

2. The vesicle of claim 1 , wherein the intercorneocyte lipid component includes 5 wt % to 60 wt % of ceramide, 5 wt % to 35 wt % of a cholesterol derivative containing cholesterol or a phytosterol derivative containing phytosterol, and 5 wt % to 60 wt % of a higher fatty acid based on a total weight of the intercorneocyte lipid component.

3. The vesicle of claim 2 , wherein the higher fatty acid is obtained by mixing palmitic acid:stearic acid: oleic acid:linolenic acid in a weight ratio of 1 to 5:1 to 10:1 to 6:1 to 4.

4. The vesicle of claim 1 , wherein the vesicle enhances a skin barrier function and a skin moisturizing effect by increasing expression of filaggrin, laminin-5, and type-4 collagen.

5. A composition for skin external application comprising the vesicle containing the saccharide isomerate, the hydrolyzed lupine protein, and the intercorneocyte lipid mimetics as the active ingredient according to claim 1 .

6. The composition of claim 5 , wherein the composition comprises one type of formulation selected from the group consisting of a liquid, a suspension, an emulsion, a gel, a cream, an ointment, a spray, and a paste.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2017
From: ANH, TAE-JIN; SHIN, TAE-SEOG; LEE, SEUNG-JIN; LEE, MIN-HYE; KO, YOUNG-CHUL; YOO, KANG-MIN; HONG, SEUNG-KI; LEE, JIN-SOO
To: CMS LAB INC.
Reel/Frame 044194/0612 →
Priority Claims (1)
KR 10-2016-0155408 · Nov 22, 2016 · national
Continuity (1)
Related Publication 20180140528A1 · May 24, 2018